CorWave Achieves ISO 13485 Certification, Advancing Commercialization Plans for Innovative Heart Failure Devices
CorWave, a clinical-stage medical technology company focused on developing next-generation cardiac assist devices, has announced a significant regulatory achievement with the certification of its Quality Management System (QMS) under the internationally recognized ISO 13485 standard. The certification represents an important milestone in the company’s journey toward commercializing its innovative implantable Left Ventricular Assist Devices (LVADs), reinforcing its commitment to quality, patient safety, and regulatory compliance.
The certification was granted following an extensive assessment conducted by an independent notified body and covers the complete lifecycle of CorWave’s LVAD technology, including design, development, manufacturing, distribution, and servicing. By securing ISO 13485 certification, the company demonstrates that its operational processes meet stringent international requirements established for medical device manufacturers and that it has built the organizational framework necessary to support future clinical and commercial activities.
A Key Milestone for a Growing Medical Technology Company
For companies developing advanced medical devices, achieving ISO 13485 certification is widely regarded as a critical step toward regulatory approval and commercialization. The standard serves as the global benchmark for quality management systems within the medical device industry and is recognized by healthcare regulators around the world.
The certification validates that a company has implemented robust processes to ensure consistent product quality, effective risk management, regulatory compliance, and patient safety throughout the development and manufacturing process. It also establishes systems for traceability, documentation, and continuous improvement, all of which are essential requirements for bringing complex medical technologies to market.
For CorWave, the achievement reflects years of work devoted to building the operational infrastructure necessary to support its innovative cardiac assist technology. As the company advances toward pivotal clinical trials and eventual commercialization, the certification provides an important foundation for future regulatory interactions and market expansion efforts.
Supporting Innovation in Advanced Heart Failure Treatment
CorWave is focused on addressing one of the most challenging areas in cardiovascular medicine: advanced heart failure. Heart failure affects millions of people worldwide and remains a leading cause of hospitalization and mortality despite significant advances in treatment.
For patients with severe forms of heart failure, particularly those awaiting heart transplantation or those who are not eligible for transplant procedures, Left Ventricular Assist Devices can provide life-sustaining support. These implantable mechanical pumps help the weakened heart circulate blood throughout the body, improving organ function and quality of life.
However, traditional ventricular assist devices remain highly complex technologies that require sophisticated engineering, precise manufacturing, and rigorous quality control measures. Because these devices directly support critical cardiac function, ensuring reliability and safety throughout the product lifecycle is of paramount importance.
CorWave has been developing innovative LVAD technology designed to advance the field of mechanical circulatory support. The company’s efforts focus on creating devices capable of improving patient outcomes while addressing some of the limitations associated with existing technologies.
The newly obtained ISO certification demonstrates that CorWave has established the systems and procedures necessary to support the development and future commercialization of these advanced cardiac devices.
Certification Covers the Entire Product Lifecycle
One of the most notable aspects of the certification is its broad scope. Rather than focusing on a limited portion of operations, the ISO 13485 certification encompasses the entire lifecycle of CorWave’s implantable ventricular assist devices.
This includes the earliest stages of product design and development, where engineering teams work to create innovative solutions and validate performance. It also covers manufacturing processes, ensuring that products are produced consistently according to strict quality standards.
In addition, the certification extends to distribution and servicing activities, highlighting CorWave’s ability to manage products after they leave the manufacturing facility and throughout their use in clinical settings.
By covering every stage of the value chain, the certification demonstrates that CorWave has developed a comprehensive quality management framework capable of supporting long-term commercial operations.
The successful audit conducted by the independent notified body confirms that the company’s systems meet international expectations for medical device manufacturers and are aligned with industry best practices.
Building Confidence Ahead of Pivotal Clinical Trials
The certification comes at a strategically important time for CorWave as it prepares for the next phase of its clinical development program.
Clinical-stage medical technology companies face increasing scrutiny from regulators, healthcare providers, and investors as they move toward pivotal trials. Establishing a certified quality management system helps ensure that product development, manufacturing, and clinical activities are conducted under tightly controlled conditions.
According to CorWave Chief Executive Officer Louis de Lillers, the certification represents both a regulatory milestone and a reflection of the company’s broader commitment to excellence.
He emphasized that implantable ventricular assist devices are among the most sophisticated medical technologies currently available and noted that CorWave has invested heavily in creating the infrastructure required to design, manufacture, and distribute these products internally.
De Lillers stated that obtaining ISO 13485 certification strengthens the company’s readiness for upcoming pivotal clinical studies and provides confidence as CorWave advances toward future commercial deployment. He also highlighted the company’s dedication to supporting healthcare professionals and patients living with advanced heart failure through the development of high-quality, innovative solutions.
The certification therefore serves not only as validation of current operational capabilities but also as an important enabler for future growth.
Commitment to Patient Safety and Risk Management
A central component of the ISO 13485 framework is the implementation of rigorous risk management procedures. Medical device manufacturers must demonstrate their ability to identify, assess, and mitigate risks throughout the product lifecycle to protect patients and healthcare providers.
CorWave’s leadership highlighted patient safety as a core focus of the certification effort.
Dawn Sadlowski-Buisserez, Vice President of Operations at CorWave, expressed pride in the accomplishment and credited the company’s teams for their dedication throughout the certification process.
She noted that the successful certification reflects the organization’s commitment to robust internal controls, comprehensive risk management practices, and operational excellence. According to Sadlowski-Buisserez, these elements are essential for ensuring the safety and reliability of CorWave’s products and for maintaining the high standards required in the medical device industry.
The certification also demonstrates that the company has established systems for ongoing monitoring and continuous improvement, helping ensure that quality standards remain consistently high as operations expand.
Strengthening the Path Toward Commercialization
As CorWave continues to advance its technology, ISO 13485 certification is expected to play an important role in supporting future regulatory submissions and commercial readiness.
Many regulatory agencies around the world view compliance with ISO 13485 as a critical indicator of a manufacturer’s ability to consistently produce safe and effective medical devices. The certification can facilitate regulatory reviews, support international market access, and enhance confidence among healthcare providers and potential partners.
For investors and stakeholders, the achievement signals that CorWave has reached an important level of organizational maturity. It demonstrates that the company has moved beyond early-stage innovation and has established the operational systems necessary to support broader clinical and commercial ambitions.
Advancing a Vision for Heart Failure Patients
Ultimately, CorWave’s mission extends beyond regulatory milestones and technical achievements. The company’s long-term goal is to improve the lives of individuals living with advanced heart failure by providing innovative mechanical circulatory support technologies that enable patients to live longer, healthier, and more active lives.
The successful certification of its Quality Management System marks a major step toward realizing that vision. By establishing internationally recognized quality standards across every aspect of its operations, CorWave has strengthened its foundation for future clinical success and commercial growth.
As the company progresses toward pivotal trials and eventual market introduction of its implantable LVAD technology, the ISO 13485 certification serves as a powerful endorsement of its commitment to quality, safety, innovation, and patient care. With this achievement, CorWave moves closer to delivering transformative solutions for heart failure patients while positioning itself as a significant player in the evolving field of cardiac assist devices.
About CorWave
CorWave is a French company that develops and manufactures innovative cardiac assist devices. CorWave’s undulating membrane is a breakthrough technology that distinguishes itself from currently marketed Left Ventricular Assist Devices (LVADs) through its physiological operation, designed to reproduce pulse and blood flow velocities similar to those of a healthy heart.
Ultimately, CorWave’s membrane pump technology is designed to reduce complications associated with current devices and improve the management of patients suffering from heart failure. A member of French Tech 120, CorWave was founded in 2012 by the start-up studio MD Start and is funded by renowned investors, including Bpifrance, EIC Fund, M&L Healthcare, Novo Holdings, Seventure Partners, Sofinnova Partners, Ysios Capital, and Vlerick Group.
The company has raised over 100 million euros in equity funding and employs about a hundred people. In May 2025, after more than a decade of research and development, CorWave became the first company in over 25 years to bring a radically new pumping technology into clinical evaluation in the durable LVAD space.
